Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

5 things to know about Alex Azar’s first hearing as nominee for HHS Secretary

One Republican said he wouldn't support the nomination of Alex Azar, if the former pharmaceutical executive can't support importation of pharmaceuticals from other countries. 

Letting states pick essential health benefits may ‘undermine’ ACA

Insurers, hospitals and regulators had a largely negative reaction to a major provision of the proposed Affordable Care Act (ACA) benefit parameters for 2019 that would allow states to define their own “essential health benefits” which ACA-compliant insurance plans have to cover, saying it may return the nongroup market to its pre-ACA state.

Thumbnail

VA hospitals failed to report potentially dangerous physicians

The U.S. Department of Veterans Affairs (VA) failed to report disciplinary action taken against providers and delayed reviews of complaints against physicians, according to a report from the Government Accountability Office (GAO).

Thumbnail

States warn CHIP recipients benefits may end in January

Nearly two months after authorization for the Children’s Health Insurance Program (CHIP) expired, two states are sending letters to families about the potential loss in insurance coverage for their children unless Congress approves funding—and another says it’s already out of money.

What questions await HHS nominee Alex Azar

Former Eli Lilly executive and President Donald Trump’s nominee to be the next HHS Secretary, Alex Azar, will face his first confirmation hearing before the Senate health committee on Nov. 29. He’s likely to get plenty of queries from Democrats on his opposition to the Affordable Care Act (ACA) as well as his actions as a pharmaceutical executive, such as Eli Lilly’s price hikes on insulin.

‘Wave’ of healthcare bankruptcies predicted for 2018

Bankruptcy filings among healthcare companies more than tripled in 2017, according to Bloomberg, and there are signs that 2018 will bring more filings or debt restructuring from hospitals and other medical organizations.

Healthcare priorities entangled in packed Congress agenda

The congressional to-do list for December is quite long, with the Senate looking to pass major tax overhaul and the looming threat of a government shutdown. Most important for the healthcare industry is the fact that the Affordable Care Act (ACA) and the Children’s Health Insurance Program (CHIP) have become one of the many items fighting for attention on Capitol Hill.

Carolinas-UNC merger under state review

A special committee formed by the University of North Carolina’s board of governors has until Dec. 20 to review the proposed joint venture between the UNC Health Care System and Carolinas HealthCare System.

Displaying 4017 - 4024 of 6652

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup